The treatment of advanced thyroid cancer has undergone rapid evolution in the last decade,
with multiple kinase inhibitor drug approvals for each subtype of thyroid cancer and a …

Thyroid cancer is the most common malignancy of the endocrine system, encompassing
different entities with distinct histological features and clinical behavior. The diagnostic …

BACKGROUND Around 50% of cutaneous melanomas harbor the BRAF V600E mutation
and can be treated with BRAF inhibitors. DNA carrying this mutation can be released into …

Context Little is known about the frequency of key mutations in thyroid cancer metastases
and its relationship with the primary tumor genotype. Objectives To evaluate the frequency of …

Background BRAF V600 mutant circulating cell-free tumor DNA (BRAF V600mut ctDNA)
could serve as a specific biomarker in patients with BRAF V600 mutant melanoma. We …

Context Interpretation of calcitonin measurement to predict the prognosis of medullary
thyroid carcinoma (MTC) requires multiple measurements over an extended time period …

Cell-free DNA (cfDNA) quantity and quality in plasma has been investigated as a non-
invasive biomarker in cancer. Previous studies have demonstrated increased cfDNA amount …

Background Conventional biomarkers in thyroid cancer are not disease specific and
fluctuate in advanced disease, making interpretation difficult. Circulating tumour DNA …

Background Classic tissue biopsies or surgical resections are invasive procedures that
capture only a single snapshot in the evolution of cancer. In contrast, a blood-based test or …

The diagnostic approach to thyroid cancer is one of the most challenging issues in oncology
of the endocrine system because of its high incidence (3.8% of all new cancer cases in the …